A5000836360- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders
- Infectious Diseases and Mycology
- Medicine and Dermatology Studies History
- Dermatological and COVID-19 studies
- Systemic Lupus Erythematosus Research
- Dermatological and Skeletal Disorders
- Dermatology and Skin Diseases
- Cutaneous lymphoproliferative disorders research
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Cancer and Skin Lesions
- Skin Diseases and Diabetes
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Fungal Infections and Studies
- Allergic Rhinitis and Sensitization
- Veterinary Oncology Research
- COVID-19 and healthcare impacts
- Genetic and rare skin diseases.
- Contact Dermatitis and Allergies
- Sarcoidosis and Beryllium Toxicity Research
- Mycobacterium research and diagnosis
- Oral and Maxillofacial Pathology
- Skin Protection and Aging
University of Sassari
2016-2024
Health care spending in Italy is high and continues to increase; assessing the long-term health economic outcomes of new therapies essential. Atopic dermatitis (AD) a chronic, pruritic, immune-mediated inflammatory dermatosis, clinical condition that significantly affects patients' quality life at cost requires continuous care. This retrospective study aimed assess direct adverse drug reactions (ADRs) Dupilumab outcomes. All AD patients treated with Sassari University Hospital, Italy,...
Derived inflammatory indexes from routine hematological parameters might be useful for predicting early-response vs. late/non-response to dupilumab, the first biological agent approved moderate-to-severe atopic dermatitis (AD). We tested this hypothesis by retrospectively investigating association between pre-specified baseline and dupilumab response (≥50% reduction in Eczema Area Severity Index, EASI 50) at 4 16 weeks a consecutive series of 66 AD patients (38 males 28 females). Forty-six...
Background: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients' quality of life. The advent highly targeted biological therapies has transformed treatment strategies, emphasizing the importance selecting most effective and cost-efficient option. Secukinumab, an IL-17A inhibitor, demonstrated efficacy safety in treating moderate-to-severe plaque psoriasis (PsO). However, long-term real-world data on its effectiveness persistence rate...
While CD4+ T-cells are traditionally regarded as the main pathogenic T-cell subpopulation in psoriatic arthritis (PsA), role of circulating CD8+ remains poorly characterized. We evaluated differential representation subpopulations peripheral blood (PB) PsA patients.CD8+IL-17+, CD8+IFNγ+ and CD8+IL-17-IL-22+ were by flow-cytometry 25 consecutive patients, 7 rheumatoid (RA) 16 patients with psoriasis, 26 healthy controls (HC).We observed a significant expansion IFN-γ producing when compared to...
Pulmonary and extra-pulmonary diseases caused by nontuberculous mycobacteria: new clinical public health threats http://ow.ly/87Dm30eMFd9.
<i>Alternaria</i> spp may cause opportunistic mycoses in the skin after cutaneous inoculation or through blood dissemination immune-suppressed patients. Here, we describe a case of infection with 62-year-old man, presenting multifocal papules and erythematous nodules involving distal limbs bilaterally. The absence inflammatory bowel disease was confirmed by gastroenterologist. patient under treatment for uveitis unknown origin immunosuppressive doses cyclosporin prednisolone approximately 3...
Dear Editor, We read with interest the correspondence "Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated ixekizumab".1 To improve knowledge of this important topic, we would like to describe experience Dermatology Unit reference university hospital located Sassari, Italy. The COVID-19 epidemic has been causing crisis national healthcare systems worldwide. clinical management patients significantly changed. prescription biologic therapies, which could favor...